Delving into the Latest Updates on Florbetaben F-18 with Synapse

The goal of this clinical trial is to evaluate whether ¹⁸F-florbetaben PET/MR can detect systemic amyloid deposits early and noninvasively in patients with monoclonal gammopathy. The main question it aims to answer is: Can ¹⁸F-florbetaben PET/MR identify systemic amyloid deposits across clinically and histologically defined patient groups?
Participants will:
* Be screened for eligibility and asked to sign an informed consent form
* Have their vital signs measured
* Receive a single intravenous injection of approximately 300 MBq ¹⁸F-florbetaben (Neuraceq®), followed by whole-body PET/MR imaging from skull base to below the kidneys. If MRI is contraindicated (e.g., pacemaker, severe claustrophobia), PET/CT will be performed instead. The scan takes approximately one hour, during which participants lie still in the scanner
* Be monitored during and after the scan for any side effects or adverse events
* Complete study participation at the end of the imaging session (single visit, no follow-up required)

Start Date01 Oct 2026

Sponsor / Collaborator

University of Zurich

NCT07169630

/ RecruitingPhase 1IIT

PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer s Disease (AD) or Mild Cognitive Impairment (MCI)

Background:
About 5 million adults in the United States have age-related brain disorders. These include Alzheimer disease (AD), mild cognitive impairment (MCI), and other dementias. The number of people with these disorders will likely increase as the population ages and life span increases. Inflammation is thought to play a role in AD and MCI. Researchers want to know if an enzyme called PDE4B increases inflammation in people with AD or MCI.
Objective:
To test whether medical imaging using a new radiotracer ([18F]PF-06445974) can measure PDE4B in the brains of people with AD or MCI.
Eligibility:
People aged 50 years and older with AD or MCI. Healthy volunteers are also needed.
Design:
Participants will have up to 5 clinic visits with 3 imaging scans of the brain.
They will have be screened. They will have a physical exam with blood tests. This will include tests of their heart and nerve function, including memory.
Participants will have 2 positron emission tomography (PET) scans. One will use a standard radiotracer. The other will use the study radiotracer. They will receive each tracer through a tube attached to a needle inserted into a vein. During the scan with the study tracer, participants will have a second tube inserted into a vein in the wrist; this tube will be used to draw blood during the scan. Participants will lie on a bed that slides into a doughnut-shaped machine. These visits will take about 6 hours each.
Participants will have 1 magnetic resonance imaging (MRI) scan. They will lie on a bed that slides into a cylinder. This visit will take up to 2 hours....

Start Date26 Aug 2026

Sponsor / Collaborator

National Institute of Mental Health

NCT07758660

/ Enrolling by invitationPhase 2IIT

Alzheimer's Disease Research Center PET Component

The purpose of this study is to further engage and characterize Alzheimer's Disease Research Center (ADRC) participants through additional research opportunities, particularly PET imaging. Amyloid and Tau PET imaging will be collected in 24 participants per year, for a total of 120 participants over five years.
All participants will be followed longitudinally, including through potential transitions from normal aging to mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD).

Start Date06 Aug 2026

Sponsor / Collaborator

Columbia University

[+1]

100 Clinical Results associated with Florbetaben F-18

Login to view more data

100 Translational Medicine associated with Florbetaben F-18

Login to view more data

100 Patents (Medical) associated with Florbetaben F-18

Login to view more data

215

Literatures (Medical) associated with Florbetaben F-18

01 May 2026·JPAD-Journal of Prevention of Alzheimers Disease

Discordance in amyloid positivity between visual reads and Centiloids: Impact of white matter uptake

Article

Author: Devanarayan, Viswanath ; Reyderman, Larisa ; Kramer, Lynn D ; Charil, Arnaud ; Irizarry, Michael C ; Reilhac, Anthonin ; Dhadda, Shobha ; Nelson, Todd M

BACKGROUND:

The visual interpretation of amyloid PET scans, or visual read (VR), is the most common technique used in clinical practice to identify the presence of cerebral amyloid plaques. Amyloid status (positive or negative) determined by VR or using a Centiloid (CL) cut-off shows high overall concordance. However, discordant cases can occur where the VR is positive, but the CL is below the positivity cut-off, or vice versa.

OBJECTIVES:

The objective of this analysis was to evaluate the rate of discordance and explore potential causes, particularly the role of amyloid tracer uptake in the white matter (WM), when determining amyloid status using VR and CL in screening for the elenbecestat phase 3 studies in early Alzheimer's disease (AD).

DESIGN:

Amyloid PET scans using either Florbetapir (Amyvid™), Florbetaben (Neuraceq™) or Flutemetamol (Vizamyl™) from 3,232 participants (1507 VR- and 1725 VR+) with cognitive impairment screened for the elenbecestat phase 3 studies in early AD were visually interpreted at screening by trained neuroradiologists and quantified using CL values.

SETTING:

Academic and clinical centers INTERVENTION/MEASUREMENTS: Quantitatively, amyloid positivity was defined as CL > 32.21. The number of positive cortical regions was determined by counting the number of regions with a standardized uptake value ratio (SUVr) that exceeded 1.17. PET SUVr levels in the cerebral WM were measured using an eroded WM region of interest (ROI). Statistical tests were conducted to detect differences among the four concordance groups, defined by the relationship of VR and CL status (positive or negative). Additionally, tests examined the relationship between uptake in the WM and rates and type of discordance. Receiver operating characteristic (ROC) analysis and DeLong's test were also used to examine the effect of different tracers on the discordant rates.

RESULT:

Discordance was observed in 6.53% of cases (n=211), with VR+/CL- in 4.61% (n=149) and VR-/CL+ in 1.92% (n=62). VR+/CL- discordant cases had significantly fewer amyloid-positive cortical regions compared to both VR+/CL+ and VR-/CL+ cases. VR-/CL+ cases had a significantly higher WM uptake than VR-/CL- and VR+/CL- cases. Our findings revealed a relationship between WM uptake and rates and types of discordance. High WM uptake can erroneously lead to CL+, due to gray matter (GM) contamination from the WM, and VR- status, due to reduced contrast between WM and GM, resulting in VR-/CL+ cases. Conversely, low WM uptake can result in an underestimation of CL values, inaccurately classifying a scan as CL-, and at the same time, the increased contrast may result in a VR+, thereby increasing the occurrence of discordant VR+/CL- cases.

CONCLUSION:

Variations in WM uptake significantly contribute to discordances by introducing positive or negative bias in CL values and altering the GM to WM contrast, which forms the basis of the VR. Nevertheless, the rates of discordant cases are low and VR represents a robust and validated method to determine the presence of amyloid deposition. VR enables enrolling patients with amyloid beta pathology, as seen on amyloid PET scans, whereas CL scaling was developed to provide standardized units that more consistently characterize longitudinal amyloid‑β change. These findings reflect the complementary roles of VR and CL in amyloid PET evaluation, with implications for refining diagnostic accuracy and disease monitoring in AD clinical trials and practice.

01 May 2026·JOURNAL OF NUCLEAR CARDIOLOGY

An era of precision: Emerging, research, and adjunct radiotracers for nuclear imaging of cardiac amyloidosis

Review

Author: Martin, Emily B ; Wall, Jonathan S

Cardiac amyloidosis (CA) has rapidly transitioned from an underrecognized cause of heart failure to a treatable protein-misfolding cardiomyopathy, driven by advances in transthyretin (TTR) stabilization and gene silencing, and immunotherapy to control monoclonal light chain production. Noninvasive diagnosis of transthyretin cardiac amyloidosis (ATTR) using technetium-99m bone-avid scintigraphy is now routine, yet these tracers do not bind amyloid and offer limited amyloid specificity, quantification, or monitoring of response to therapy. Positron emission tomography (PET) and single-photon emission computed tomography (SPECT) agents that directly engage amyloid or key downstream processes (fibroblast activation, inflammation, denervation) may redefine the diagnostic algorithm, phenotyping, risk stratification, and longitudinal assessment. Among these, iodine [¹²⁴I]evuzamitide (AT-01), a radioiodinated, pan-amyloid-binding peptide targeting amyloid fibrils and amyloid associated heparan sulfate proteoglycans, has emerged as the first amyloid-specific PET radiotracer to receive U.S. FDA Breakthrough Therapy designation for CA and has completed a Phase 3 pivotal evaluation. [¹⁸F]Florbetaben is similarly poised in a pivotal Phase 3 study. Herein, we summarize 1) Emerging radiotracers primed for clinical availability, including the pan-amyloid peptide tracers, [¹²⁴I]evuzamitide and [^99mTc]p5+14, the stilbene-based small molecule [¹⁸F]florbetaben, and the protein-based radiotracer, [^99mTc]aprotinin; 2) Research-focused, Aβ amyloid radiotracers and their performance in CA ([¹¹C]PiB; [¹⁸F]florbetapir, [¹⁸F]flutemetamol; and newer [¹⁸F]florbetazine); and 3) Adjunct radiotracers for exploring myocardial microenvironment ([⁶⁸Ga]FAPI, and others), emphasizing rationale for use, opportunities, synergies, strengths, limitations, and regulatory status. Finally, we outline future research and molecular targets to elucidate the pathology and the impact of novel amyloid therapeutics as they become available.

01 Mar 2026·Journal of Nuclear Medicine Technology

Quantitative Amyloid Brain Imaging: A Literature Review of the Centiloid Scale in Alzheimer Disease Evaluation

Review

Author: York, Benjamin ; Doroudinia, Abtin ; Colletti, Patrick M

Amyloid PET has become a pivotal imaging biomarker for Alzheimer disease (AD), enabling in vivo detection and quantification of β-amyloid deposition. However, variability in quantitative measurements across tracers, scanners, and analysis methods has considerably limited direct comparison of amyloid burden between studies and centers. To address this issue, the Centiloid Project has been developed to provide a standardized quantitative scale for amyloid PET, harmonizing results across tracers and institutions. In this literature review, we aim to summarize current evidence on the development, validation, and clinical application of the Centiloid scale in amyloid PET imaging, emphasizing its methodologic foundations, tracer-specific conversions, and diagnostic thresholds. Methods: A literature review was conducted using PubMed, Scopus, and Embase databases from January 2015 through October 2025. Search terms included "amyloid PET," "Centiloid," "SUVR," and "Alzheimer disease." We reviewed articles with quantitative amyloid PET analyses and Centiloid conversion and studies which compared multiple tracers using MIMneuro software Centiloid calibration. Results: The Centiloid method demonstrates strong intertracer and interscanner harmonization when standardized to the ¹¹C-Pittsburgh compound B reference, with high correlation (r ² > 0.9) across ¹⁸F-labeled tracers, including florbetapir, flutemetamol, and florbetaben. Most articles identified a Centiloid threshold between 20 and 25 Centiloids as indicative of significant amyloid pathology. Implementation of the Centiloid framework improved comparability across clinical trials and longitudinal studies, facilitating integration into the AT(N) research framework. Conclusion: The Centiloid scale represents a critical advancement in quantitative amyloid PET imaging, providing a universal reference that enhances data reproducibility, cross-trial comparisons, and clinical decision-making. Continued work is needed to expand standardization for novel tracers and hybrid imaging systems, ensuring full clinical translation of this metric in dementia imaging.

34

News (Medical) associated with Florbetaben F-18

18 Aug 2026

·www.prnewswire.com

Cortechs.ai Announces FDA Clearance for NeuroQuant® PET: Advancing Molecular Imaging for Cognitive Impairment

COVINGTON, Ky., Aug. 18, 2026 /PRNewswire/ -- NeuroQuant ® PET has received FDA 510(k) clearance (K261916) for PET. NeuroQuant PET ® aids physicians in the evaluation of patient pathologies and the clinical interpretation of PET performed for the assessment of cognitive impairment and other neurological conditions. Continue Reading NeuroQuant ® PET by Cortechs.ai has received FDA 510(k) clearance (K261916) for PET. As molecular imaging plays an increasingly central role in the diagnosis and management of Alzheimer's disease and related neurodegenerative disorders, the demand for standardized, objective PET analysis continues to grow. NeuroQuant® PET is designed to deliver fully automated quantification, regional analysis, and structured reporting directly into routine clinical workflows. "Automated quantitative PET imaging represents the next frontier in precision and personalized medicine for Alzheimer's disease and related neurocognitive disorders. These new technological advancements are enabling the shift from phenotype-based assessment to a biological, biomarker-driven approach in assessing neurodegenerative disease. I am excited about the role NeuroQuant PET will play in shaping the future of how these conditions are understood and managed." said Dr. Ana Franceschi, M.D., Ph.D. The platform provides atlas-based quantification for amyloid PET tracers, generating standardized uptake value ratios (SUVRs) and structured reports to support consistent, data-driven interpretation. NeuroQuant® PET segments regions of interest and quantifies Centiloids for commonly used amyloid PET tracers flutemetamol, florbetaben, and florbetapir, enabling standardized comparison across tracers and imaging systems. Compatible with PET-CT, PET-MR, and PET-only workflows, NeuroQuant® PET features fully automated processing and PACS-ready outputs designed to integrate quantitative metrics into existing workflows. "NeuroQuant® PET reflects our commitment to advancing quantitative imaging in dementia care, giving clinicians objective, reproducible measurements they can trust, so patients get earlier answers and more confident treatment decisions" said Kyle Frye, CEO of Cortechs.ai. "With FDA 510(k)-clearance status, we look forward to expanding access to standardized PET quantification that supports precision medicine in Alzheimer's disease and related dementias." About Cortechs.ai Cortechs.ai is the leader in AI applications in radiology, leveraging advanced technologies in medical imaging to enhance disease screening and timely assessment, empowering healthcare providers to deliver better outcomes for patients. The company develops and markets innovative medical imaging solution software for assessing neurological disorders such as Alzheimer's disease, epilepsy, multiple sclerosis, brain trauma, tumors and prostate cancer, helping clinicians identify and monitor clinically significant cases. Cortechs.ai's industry-leading imaging solutions offer radiologists, oncologists, and urologists streamlined, cost-effective tools to assist in the assessment of brain and prostate health, including cancer evaluation. Visit  for additional insights and follow us on Twitter, LinkedIn, and Facebook. For more information, please contact: [email protected] +1 858 459 9700 SOURCE Cortechs.ai 21% more press release views with Request a Demo

15 Aug 2026

·www.fiercebiotech.com

Curium strikes up to $8B deal for radiopharma rival Lantheus

Months after reports first linked Curium to a potential Lantheus takeover, the radiopharma players have made it official with a deal worth up to $8 billion. Curium has agreed to buy all outstanding Lantheus shares for $102.50 apiece in cash at closing. Shareholders could receive up to another $12 per share through contingent value rights tied to sales milestones for Lantheus’ prostate cancer, neurology and Definity franchises through 2030. The companies expect to close the transaction in the first half of 2027, subject to approval from Lantheus shareholders and regulators. If the deal is completed, Lantheus will become a privately held company. In May, Lantheus was reportedly considering a Curium proposal that valued the Massachusetts company at roughly $7 billion. At the time, both companies declined to comment on the takeover chatter. The tie-up would unite Curium’s global manufacturing network and theranostics pipeline with Lantheus’ sizable U.S. radiodiagnostics business. The combined company would operate across the nuclear medicine supply chain, from isotope production and manufacturing to diagnostic imaging and targeted radionuclide therapy. Curium said the merged operation would serve patients in oncology, neurology and cardiology across more than 70 countries. The privately held company, which is controlled by investment firm CapVest Partners, employs more than 3,800 people and operates over 80 manufacturing sites worldwide. Lantheus brings several established products to the table, led by prostate cancer PET imaging agent Pylarify. Its portfolio also includes the cardiac ultrasound enhancing agent Definity and beta-amyloid PET imaging agent Neuraceq. The company generated $377.3 million in worldwide revenue during the first quarter of 2026, with those three products providing much of the haul. Lantheus is scheduled to release second-quarter results Aug. 6 but will skip its accompanying conference call and suspend its 2026 guidance because of the pending transaction. Lantheus has spent the past several years broadening its presence in radiopharmaceuticals through a string of deals. In 2025, it agreed to pay $250 million upfront to acquire Evergreen Theragnostics, gaining a radiopharma development operation, manufacturing infrastructure and a pipeline that included the neuroendocrine tumor diagnostic Octevy. The deal carried up to $752.5 million in additional milestone payments. Lantheus acquired Meilleur Technologies in 2024 and Life Molecular Imaging in 2025 as it built up its Alzheimer’s imaging portfolio. Lantheus has faced some recent pipeline turbulence. In June, the FDA declined to approve its application for the neuroendocrine tumor imaging kit LNTH-2501 because of unresolved manufacturing conditions at a third-party facility. The agency did not raise concerns about the candidate’s safety, efficacy or supporting clinical data. Last year, Lantheus and its partner Eli Lilly abandoned plans to pursue an FDA approval for their potential PSMA-directed therapeutic challenger to Novartis’ blockbuster Pluvicto following an unfavorable overall survival readout from a phase 3 trial in metastatic castration-resistant prostate cancer. The content above comes from the network. if any infringement, please contact us to modify.

AcquisitionClinical Result

03 Aug 2026

·firstwordpharma.com

Curium bets $8B on Lantheus to expand radiopharma footprint

With rumours swirling about a potential jumbo merger between AstraZeneca and Bristol Myers Squibb, and Supernus agreeing to combine with Indivior, a couple of radiopharma specialists added to the M&A buzz on Monday.Curium inked a deal to merge with Lantheus in a transaction that could be worth up to about $8 billion. "This combination unlocks an opportunity that neither company could achieve alone," said Curium CEO Renaud Dehareng. The announcement follows rumours in late May of a possible takeout worth up to $7 billion, anonymous sources suggested in a media report at the time."Lantheus' complementary business accelerates our strategy with a robust US commercial infrastructure, a complementary F18-isotope based prostate diagnostics franchise and marks our entry in the US market for diagnostic solutions targeting neurology and echocardiography," Dehareng said, adding the merged entity will "provide meaningful theranostic options to patients from SPECT and PET diagnostics to targeted radioligand therapy across the globe."Lantheus' already marketed products include Pylarify (piflufolastat F 18), a PSMA PET imaging agent used to detect prostate cancer, DEFINITY (perflutren liquid microsphere) for cardiac ultrasound enhancement, and Neuraceq (florabetaben F18) for beta-amyloid PET imaging. However, the company received a complete response letter from the FDA in June for a gallium-68 edotreotide PET imaging agent called LNTH-2501 for somatostatin receptor-positive neuroendocrine tumours. The agency cited unresolved third-party manufacturing issues rather than concerns over safety or efficacy.Under the agreed terms, Lantheus shareholders will receive $102.50 per share in cash at closing, along with contingent value rights (CVRs) that could provide up to an additional $12 per share. That brings the total potential consideration up to $114.50 per share, assuming various commercial milestones are achieved through 2030.The CVRs are tied to sales targets across Lantheus' prostate cancer diagnostics portfolio, including Pylarify and future PSMA-targeted radiodiagnostics; the neurology diagnostics business, including Neuraceq and next-gen amyloid and tau imaging agents MK-6240, NAV-4694 and LNTH-2620; and its DEFINITY business, including perflutren-based microbubble technology products.Lantheus' board has unanimously approved the transaction and the merger is expected to close in the first half of 2027.

AcquisitionDiagnostic Reagents

100 Deals associated with Florbetaben F-18

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Florbetaben F-18	V09AX06	DB09148

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Alzheimer Disease	United States	Lantheus Medical Imaging, Inc.	19 Mar 2014
Alzheimer Disease	United States	Lantheus Holdings, Inc.	19 Mar 2014
Cognitive Dysfunction	European Union	Lantheus Holdings, Inc.	20 Feb 2014
Cognitive Dysfunction	Iceland	Lantheus Holdings, Inc.	20 Feb 2014
Cognitive Dysfunction	Liechtenstein	Lantheus Holdings, Inc.	20 Feb 2014
Cognitive Dysfunction	Norway	Lantheus Holdings, Inc.	20 Feb 2014
Diagnostic agents	European Union	Lantheus Holdings, Inc.	20 Feb 2014
Diagnostic agents	Iceland	Lantheus Holdings, Inc.	20 Feb 2014
Diagnostic agents	Liechtenstein	Lantheus Holdings, Inc.	20 Feb 2014
Diagnostic agents	Norway	Lantheus Holdings, Inc.	20 Feb 2014

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Immunoglobulin Light-Chain Amyloidosis	Phase 3	United States	Lantheus Holdings, Inc.	13 Jan 2023
Immunoglobulin Light-Chain Amyloidosis	Phase 3	Germany	Lantheus Holdings, Inc.	13 Jan 2023
Immunoglobulin Light-Chain Amyloidosis	Phase 3	Spain	Lantheus Holdings, Inc.	13 Jan 2023
Immunoglobulin Light-Chain Amyloidosis	Phase 3	United Kingdom	Lantheus Holdings, Inc.	13 Jan 2023
Senile cardiac amyloidosis	Phase 3	United States	Lantheus Holdings, Inc.	13 Jan 2023
Senile cardiac amyloidosis	Phase 3	Germany	Lantheus Holdings, Inc.	13 Jan 2023
Senile cardiac amyloidosis	Phase 3	Spain	Lantheus Holdings, Inc.	13 Jan 2023
Senile cardiac amyloidosis	Phase 3	United Kingdom	Lantheus Holdings, Inc.	13 Jan 2023
Transthyretin Amyloid Cardiomyopathy	Phase 3	United States	Lantheus Holdings, Inc.	13 Jan 2023
Transthyretin Amyloid Cardiomyopathy	Phase 3	Germany	Lantheus Holdings, Inc.	13 Jan 2023

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03706261 (CTgov)	Phase 1	Alzheimer Disease	145	18F-Florbetaben+18F-MK-6240	awgvrqyhwp(fxuskamjlg) = bhryjjxovz tkqiwbkufp (nbodaqxgkk, 0.23) View more	-	01 Aug 2025
NCT02831283 (CTgov)	Phase 2	Alzheimer Disease \| Inflammation	60	11C-PBR28+18F-Florbetaben (Amyloid-positive With Cognitive Impairment (AD))	ypfstxjcty(fawmxzofjv) = hsfxygbwii agkzylzmzk (ivqzdpfvpj, 0.18) View more	-	05 Mar 2025
				11C-PBR28+18F-Florbetaben (Amyloid-positive Without Impairment (Preclinical AD))	ypfstxjcty(fawmxzofjv) = kdtrwbbxkn agkzylzmzk (ivqzdpfvpj, 0.16) View more
NCT01222351 (CTgov)	Not Applicable	Alzheimer Disease \| Cognitive Dysfunction	161	BAY 94-9172 (Florbetaben)	qqsgvelbyw = xfnzvbfwli qswkgeacvy (uubshqzhpu, tkmdxwmqva - hqtpkonemy) View more	-	06 May 2024
NCT03744312 (CTgov)	Phase 1/2	Alzheimer Disease \| Inflammation	9	Florbetaben+11C-ER176 (Cognitive Impairment)	seruhrjxwv(rboyaxrupr) = hvdlohqgej nidijdonxl (pinriamyrn, edisiplfau - tnucecctko) View more	-	13 Sep 2023
				Florbetaben+11C-ER176 (No Cognitive Impairment)	seruhrjxwv(rboyaxrupr) = vjjxsvozkm nidijdonxl (pinriamyrn, addcaggiph - mejckrbpaq) View more
NCT02681172 (CTgov)	Phase 4	Alzheimer Disease	218	florbetaben	qgddlexmpe = emhjyavnee sbaikqobcu (kzkkpdussv, stcaabnzpi - nckxtnjmwd) View more	-	02 Nov 2018
NCT02681172 (AAIC2017)	Phase 4	Mild dementia	205	Florbetaben PET imaging	wcmcyjlspl(jwwxoxxqby) = mriczwlszt umismfuaij (xorsnkejtn, 59.9 - 73.2) View more	-	01 Jul 2017
NCT01020838 (Pubmed \| J Nucl Med)	Phase 3	Alzheimer Disease \| Cerebral Amyloid Angiopathy	82	18F-Florbetaben (In-person-trained interpreters)	tgyoodppca(fyppgzdymh) = jwvhzxwtdx ppphyimnik (bjracliwbj ) View more	-	01 Jun 2016
				18F-Florbetaben (Electronic training method)	tgyoodppca(fyppgzdymh) = poglpjkhsi ppphyimnik (bjracliwbj ) View more
NCT01020838 (Pubmed \| Alzheimers Dement)	Phase 3	Alzheimer Disease β-amyloid-positive	216	Florbetaben PET imaging	mfljjdnqky(aehyrcqocr) = ugjmtfwkfo nfgozewhrg (wdxiyxodsz, 93.8 - 100) View more	-	01 Aug 2015
NCT01138111 (Pubmed \| J Neurol Neurosurg Psychiatry)	Phase 1	Alzheimer Disease	45	18F-florbetaben (FBB+)	boqkqojvlx(rppoqrsafx) = brzdoyxwne wyagdqxxwn (ihxvhhmtgx ) View more	-	01 Apr 2015
				18F-florbetaben (FBB-)	kvztgdazpf(cnffhwkyrm) = rcfrsknpvz ahvfqzcyiw (tmwuaeecvy )
AAIC2013	Not Applicable	Alzheimer Disease	-	florbetaben (AD patients)	pbxwviwcdh(toutqitxku) = yrbfxkjneq npcadiujdb (oevgjgtbbn, 0.77 - 0.86) View more	-	01 Jul 2013
				florbetaben (Healthy volunteers)	gaylhntpul(nsymmqtmwm) = araeezruqv aakskkwtcw (mycesjsoqm, 73.9 - 88.2)